For testing combined treatment with pembrolizumab (anti-PD-L1), a randomized, double-blind phase III KEYNOTE-598 study (NCT03302234) showed that in patients with metastatic NSCLC, adding ipilimumab to pembrolizumab did not improve efficacy and exhibited greater toxicity than pembrolizumab monotherapy (71). The gene discussed is CD274; the disease is non-small cell lung carcinoma.